Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Looking for participantsNCT06762405
What this trial is testing

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Who this might be right for
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
Centre Hospitalier Universitaire Dijon 68
Testing effectiveness (Phase 2)Looking for participantsNCT07750951
What this trial is testing

Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Who this might be right for
MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Xijing Hospital 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT04751370
What this trial is testing

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT07160647
What this trial is testing

The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)

Who this might be right for
dMMR/MSI-H-type Rectal Adenocarcinoma
Sir Run Run Shaw Hospital 29
Not applicableUnknownNCT05645094
What this trial is testing

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

Who this might be right for
Locally Advanced Rectal CarcinomaMSI-High
Fudan University 38